HHS Drug Pricing Plan: Mum On National Cost Effectiveness Program, Cautious On QALYs
Biopharma likely approves of the Administration’s concern that QALYs, a commonly used metric in cost effectiveness evaluations, may not be appropriate for drug pricing reform policies because it could disadvantage people with disabilities.
You may also be interested in...
CMMI payment demonstrations are viewed as way of skirting statutory obstacles to experimenting with new approaches to reimbursement and could lead to significant drug pricing reforms if legislative efforts fail. However, HHS is not signaling an intent to pursue transformational new models at this point.
Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.
340B Hospitals Charging Private Insurers Nearly Four Times Acquisition Costs On Cancer Drugs – Study
New report makes a case for further scrutiny of the 340B program's contributions to high drug costs, although manufacturers remain the main target of legislative and regulatory reform proposals.